Patents by Inventor Kazuo Tsubota

Kazuo Tsubota has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12023513
    Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: July 2, 2024
    Assignees: Toshiba Materials Co., Ltd., Tsubota Laboratory, Inc.
    Inventors: Masahiko Yamakawa, Hidemasa Torii, Toshihide Kurihara, Kazuo Tsubota
  • Publication number: 20240210736
    Abstract: A model that closely resembles human excessive myopia can be prepared by mounting a minus lens (2) and a protector (4) to a juvenile mouse, the minus lens having an angle and a width adjustable in response to growth of the mouse. Further, this model analysis shows that myopia induction causes endoplasmic reticulum stress in a sclera and the endoplasmic reticulum stress induces myopia. Furthermore, it is revealed that an endoplasmic reticulum stress suppressant, particularly, phenylbutyrate and tauroursodeoxycholic acid act as a myopia prevention/suppression agent.
    Type: Application
    Filed: March 11, 2024
    Publication date: June 27, 2024
    Applicant: TSUBOTA LABORATORY, INC.
    Inventors: Shinichi IKEDA, Xiaoyan JIANG, Kazuo TSUBOTA, Toshihide KURIHARA
  • Publication number: 20240165422
    Abstract: The present disclosure relates to an apparatus and method for controlling biological function by stimulation by light of a specific wavelength, such as violet light, which is irradiated at a specific blinking frequency, and an apparatus and method for improving light environment. An illustrative apparatus for controlling biological function includes at least one light source 10 which irradiates light of a specific wavelength, and a controller 20 which is configured to control irradiation conditions including a blinking frequency of the light source 10.
    Type: Application
    Filed: March 18, 2022
    Publication date: May 23, 2024
    Inventors: Motoshi HAYANO, Kazuo TSUBOTA, Yasue MITSUKURA
  • Publication number: 20240148766
    Abstract: An object of the present invention is to provide a novel agent for adjusting hardness of a lens of an eye which can be taken easily, conveniently, and safely for a long-term, can effectively adjust the hardness of the lens, and is capable of preventing, alleviating and improving poor focus and decreased near visual acuity, such as presbyopia, caused by aging and various diseases. The present invention solves the above object by providing an agent for adjusting hardness of a lens of an eye comprising a glycosyl hesperetin as an active ingredient.
    Type: Application
    Filed: November 15, 2021
    Publication date: May 9, 2024
    Inventors: Yosuke NAKAZAWA, Naoki MORISHITA, Shin ENDO, Masaki MIYAKE, Hitoshi MITSUZUMI, Motoshi HAYANO, Kazuo TSUBOTA
  • Patent number: 11932679
    Abstract: The purpose of the present invention is to provide an agent for restoring a visual function or an agent for preventing the deterioration in a visual function, which has an excellent visual function restoring ability. The agent for regenerating a visual function or the agent for preventing the deterioration in a visual function according to the present invention contains, as an active ingredient, a chimeric protein having both an amino acid sequence for a microorganism-origin ion-transporting receptor rhodopsin and an amino acid sequence for an animal-origin G-protein-coupled receptor rhodopsin. The chimeric protein is preferably one in which an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the amino acid sequence for the microorganism-origin ion-transporting receptor rhodopsin is substituted by an amino acid sequence for a cytoplasm-side second loop and/or a cytoplasm-side third loop in the G-protein-coupled receptor rhodopsin.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: March 19, 2024
    Assignees: Keio University, Nagoya Institute of Technology
    Inventors: Toshihide Kurihara, Yusaku Katada, Hiromitsu Kunimi, Kazuo Tsubota, Hideki Kandori
  • Publication number: 20240041806
    Abstract: The present invention provides a screening method for searching a component inhibiting the PERK pathway and/or the ATF6 pathway, and by obtaining, by the screening method, an active ingredient inhibiting myopia progression without impairing normal growth of the eyeballs (emmetropization) in children, provides eyedrops and a composition containing the active ingredient. The problems are solved by eyedrops for inhibiting myopia progression in children containing, as an active ingredient, an inhibitor of the PERK (PKR-like endoplasmic reticulum kinase) pathway and/or the ATF6 (activating transcription factor 6) pathway. The problems are solved by a screening method for an inhibitor of myopia progression in children, including a step of contacting a candidate substance with an eye-derived cell, and a step of selecting the candidate substance using, as an index, change in a protein and/or a gene of the signal transduction system of PERK and/or ATF6.
    Type: Application
    Filed: September 1, 2021
    Publication date: February 8, 2024
    Applicant: Tsubota Laboratory, Inc.
    Inventors: Kazuo Tsubota, Toshihide Kurihara, Shinichi Ikeda, Kiwako Mori, Xiaoyan Jiang
  • Publication number: 20240033311
    Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 1, 2024
    Inventors: Kazuo TSUBOTA, Toshihide KURIHARA
  • Publication number: 20230364441
    Abstract: A device and a method for inhibiting thinning of a choroid. A choroidal thinning inhibiting device including a light source that emits violet light having a wavelength within a range from 360 nm to 400 nm, the choroidal thinning inhibiting device inhibiting thinning of a choroid by irradiation with the violet light. This device may further include a control mechanism that controls an irradiance and an irradiation time of the violet light, can be applied to ocular diseases selected from age-related macular degeneration, glaucoma, diabetic retinopathy, macular edema, eye strain, retinal vascular occlusion, triangle syndrome, central serous chorioretinopathy, retinitis pigmentosa, presbyopia, cataracts, and the like that are based on inadequate blood flow or reduced blood flow, and can be expected to prevent and treat such ocular diseases.
    Type: Application
    Filed: September 16, 2021
    Publication date: November 16, 2023
    Applicant: TSUBOTA LABORATORY, INC.
    Inventors: Xiaoyan JIANG, Kiwako MORI, Toshihide KURIHARA, Kazuo TSUBOTA
  • Patent number: 11813299
    Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: November 14, 2023
    Assignees: TSUBOTA LABORATORY, INC., ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuo Tsubota, Toshihide Kurihara
  • Patent number: 11771741
    Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.
    Type: Grant
    Filed: April 28, 2022
    Date of Patent: October 3, 2023
    Assignee: Restore Vision Inc.
    Inventors: Toshihide Kurihara, Yusaku Katada, Kazuo Tsubota, Hideki Kandori
  • Publication number: 20230248804
    Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 10, 2023
    Inventors: Toshihide Kurihara, Yusaku Katada, Kazuo Tsubota, Hideki Kandori
  • Publication number: 20230218164
    Abstract: A simple diagnosis assisting device (10) for keratoconus and/or astigmatism, including a mobile terminal (10A) including a camera (2) and a transceiver function (3), and integrally or separately provided with a light source (1) for simultaneously projecting ring light onto both eyes. The light source (1) emits the ring light upon being attached to the mobile terminal (10A) in a case of being separately provided to the mobile terminal (10A), and emits the ring light from the mobile terminal (10A) in a case of being integrally provided to the mobile terminal (10A). The camera (2) simultaneously captures a projected image of both eyes onto which the ring light is projected. The ring light may be multiplex ring light or simplex ring light, and is configured in a ring shape by a plurality of point light sources or is configured in a ring shape by a single linear light source.
    Type: Application
    Filed: March 10, 2022
    Publication date: July 13, 2023
    Applicant: TSUBOTA LABORATORY, INC.
    Inventors: Kazuo TSUBOTA, Hidenaga KOBASHI, Naoko KATO
  • Publication number: 20220402994
    Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 22, 2022
    Inventors: Toshihide Kurihara, Yusaku Katada, Kazuo Tsubota, Hideki Kandori
  • Publication number: 20220273761
    Abstract: Provided are: a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion-transporting receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin and a nucleic acid sequence encoding a signal sequence; and a nucleic acid including a nucleic acid sequence encoding a chimeric protein including at least part of an ion channeling receptor rhodopsin and at least part of a G protein-coupled receptor rhodopsin; and a nucleic acid construct including the nucleic acid sequences. The use of the nucleic acids or nucleic acid constructs prevents and suppresses the progress of retinal diseases, and enhances the visual cognitive behavioral function and visual function.
    Type: Application
    Filed: April 28, 2022
    Publication date: September 1, 2022
    Inventors: Toshihide Kurihara, Yusaku Katada, Kazuo Tsubota, Hideki Kandori
  • Patent number: 11332773
    Abstract: The present invention provides a method for evaluating tumorigenicity of a test cell, including transplanting the cell into anterior chamber of an eye of an experimental animal, and observing the presence or absence of tumor formation. According to the present invention, tumorigenicity can be evaluated in a short period and conveniently.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 17, 2022
    Assignee: KEIO UNIVERSITY
    Inventors: Shigeto Shimmura, Shin Hatou, Emi Inagaki, Kazuo Tsubota
  • Publication number: 20220025018
    Abstract: Provided are a chimeric protein of two types of rhodopsins, an ion-transporting rhodopsin and a G protein-coupled receptor rhodopsin, and a nucleic acid encoding the same, for the prevention and suppression of progression of retinal diseases, the improvement in visual cognitive behavioral functions (e.g., improvement in light-dark determination functions, improvement in bright spot evading functions, and/or crisis avoidance functions), and the enhancement of visual functions (e.g., improvement in visual acuity). The present invention also provides a method for preventing or suppressing the progression of a disease, disorder or symptom of the retina, for improving a visual cognitive behavioral function (e.g., improvement in light-dark determination functions, improvement in bright spot evading functions, and/or crisis avoidance functions), or for enhancing visual functions (e.g.
    Type: Application
    Filed: January 18, 2019
    Publication date: January 27, 2022
    Inventors: Toshihide Kurihara, Yusaku Katada, Kazuo Tsubota
  • Publication number: 20210308481
    Abstract: To provide a brain wave and cell activity control device and method based on light stimulation in which light having a specific wavelength, such as violet light, is irradiated using continuous light or a specific blinking frequency, and a device for improvement, prevention, or increase in brain function. The above-described problem is solved by a brain wave and cell activity control device, based on light stimulation, that controls brain waves or cell activity by irradiating light having a specific wavelength onto a subject using continuous light or a specific blinking frequency.
    Type: Application
    Filed: August 1, 2019
    Publication date: October 7, 2021
    Applicant: TSUBOTA LABORATORY, INC.
    Inventors: Motoshi HAYANO, Kazuo TSUBOTA
  • Publication number: 20210228901
    Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.
    Type: Application
    Filed: April 16, 2021
    Publication date: July 29, 2021
    Applicants: TOSHIBA MATERIALS CO., LTD., TSUBOTA LABORATORY, INC.
    Inventors: Masahiko YAMAKAWA, Hidemasa TORII, Toshihide KURIHARA, Kazuo TSUBOTA
  • Patent number: 11033566
    Abstract: This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 15, 2021
    Assignees: ORYZA OIL & FAT CHEMICAL CO., LTD., KEIO UNIVERSITY
    Inventors: Kazuo Tsubota, Shigeru Nakamura, Toshihiro Imada, Junji Tanaka, Takashi Kadekaru, Hiroshi Shimoda, Hiromichi Murai
  • Patent number: 11007375
    Abstract: A light source for myopia prevention article includes a light emitter to emit light having an emission spectrum continuing from a first wavelength of not less than 360 nm nor more than 400 nm to a second wavelength of more than 400 nm.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: May 18, 2021
    Assignees: Toshiba Materials Co., Ltd., Tsubota Laboratory, Inc.
    Inventors: Masahiko Yamakawa, Hidemasa Torii, Toshihide Kurihara, Kazuo Tsubota